Corcept Therapeutics Incorporated (CORT) Financial Statements
Corcept Therapeutics financial statements at a glance
Corcept Therapeutics reported revenue of $761.41 million for fiscal year 2025 (ended December 31, 2025), up 12.8% from fiscal year 2024. Net income was $98.17 million, a net margin of 12.9%, and diluted earnings per share were $0.82.
At the end of fiscal year 2025 it had total assets of $836.65 million, total liabilities of $188.85 million and shareholders' equity of $647.81 million, with cash and short-term investments of $372.15 million and total debt of $6.11 million.
Its operations brought in $142.00 million of cash; capital spending was $211,000, leaving free cash flow of $141.79 million.
The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.
Figures from company filings, in USD; latest fiscal year ended December 31, 2025.
Corcept Therapeutics Incorporated
Income Statement
Annual • USD
Corcept Therapeutics key figures by fiscal year
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $761.4M | $675.0M | $482.4M | $401.9M | $366.0M |
| Gross profit | $748.4M | $664.2M | $475.9M | $396.5M | $360.7M |
| Operating income | $44.8M | $137.0M | $107.3M | $112.6M | $124.5M |
| Net income | $98.2M | $139.7M | $105.5M | $101.3M | $112.5M |
| Diluted EPS | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 |
| Total assets | $836.7M | $840.6M | $621.5M | $583.4M | $423.8M |
| Total liabilities | $188.8M | $161.0M | $114.8M | $81.6M | $48.0M |
| Shareholders' equity | $647.8M | $679.6M | $506.7M | $501.8M | $375.8M |
| Cash and short-term investments | $372.2M | $383.3M | $368.2M | $431.7M | $223.5M |
| Total debt | $6.1M | $6.9M | $151,000 | $1.1M | $526,000 |
| Operating cash flow | $142.0M | $198.1M | $127.0M | $120.3M | $167.9M |
| Capital spending | $211,000 | $2.2M | $139,000 | $413,000 | $469,000 |
| Free cash flow | $141.8M | $195.9M | $126.9M | $119.9M | $167.4M |
In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2020.
Questions and answers
What was Corcept Therapeutics's revenue in fiscal year 2025?
$761.41 million, up 12.8% from $675.04 million in fiscal year 2024.
How much profit does Corcept Therapeutics make?
Corcept Therapeutics reported net income of $98.17 million for fiscal year 2025 (12.9% of revenue); operating income was $44.80 million.
How much cash and debt does Corcept Therapeutics have?
At the end of fiscal year 2025: cash and short-term investments of $372.15 million and total debt of $6.11 million.
What is Corcept Therapeutics's free cash flow?
$141.79 million in fiscal year 2025 (operating cash flow of $142.00 million minus capital spending of $211,000).
